This is a preview of subscription content, log in via an institution to check access.
Literatur
Campese VM, Park J. HMG-CoA-reductase inhibitors and the kidney. Kidney Int 2007; 71: 1215–22.
Haynes R, Lewis D, Emberson J et al.; SHARP Collaborative Group. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc nephrol 2014; 25:1825–33.
Colhoun HM, Betteridge DJ, Durrington PN et al.; CARDS investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin diabetes Study (CARDS). Am J Kidney Dis 2009; 54: 810–19.
Literatur
de Zeeuw D, Anzalone DA, Cain VA et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol 2015;3(3):181–90.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fritschka, E. Atorvastatin schützt die Nieren von Diabetespatienten. Info Diabetol 9, 15–17 (2015). https://doi.org/10.1007/s15034-015-0543-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15034-015-0543-z